Akèy › Skleroz Miltip › Tennessee
Etid klinik pou Skleroz Miltip nan Tennessee
6 etid pou Skleroz Miltip ap chèche patisipan nan sit nan Tennessee.
Vil nan Tennessee
Tèks ofisyèl etid la (Anglè)
A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
- Neurology Clinic PC, Cordova
Ap rekriteFaz 4
Laj 18 a 65 · Tout sèks · Mizajou Sep 30, 2026 · NCT07609719A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
- TG Therapeutics Investigational Trial Site, Franklin
- TG Therapeutics Investigational Trial Site, Knoxville
- TG Therapeutics Investigational Trial Site, Mount Juliet
- ak 2 plis
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT06433752RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
- Alliance for Multispecialty Research Clinical, Knoxville
Ap rekriteFaz 2
Laj 18 a 80 · Tout sèks · Mizajou Sep 15, 2026 · NCT07002034Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
- Hope Neurology- Site Number : 8400019, Knoxville
Ap rekriteFaz 3
Laj 18 a 60 · Tout sèks · Mizajou Sep 15, 2026 · NCT07325292A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
- Hope Neurology, Knoxville
Ap rekriteFaz 2
Laj 18 a 70 · Tout sèks · Mizajou Sep 9, 2026 · NCT06782490A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
- Neurology Clinic PC, Cordova
Ap rekriteFaz 3
Laj 18 a 65 · Tout sèks · Mizajou Jul 29, 2026 · NCT07225504Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.